23rd Annual Southwest Prostate Cancer Symposium 2018
The 23rd Annual Southwest Prostate Cancer Symposium 2018™ will bring together world-renowned experts in the management of prostate cancer and will provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.
Topics of discussion will include Genetic Markers, Prostate Pathology, mpMRI, Mapping Biopsy, Active Surveillance, Focal Therapy, Robotic Prostatectomy, Cryoablation, HIFU, Brachytherapy, IMRT/IGRT, New Approaches to Castrate Resistant Disease, Micronutrients, Morbidity Management and Testosterone Replacement Therapy.
This program aims to maximize the educational component and allow for time to explore all that the beautiful Scottsdale area offers in the spring.
This activity is designed for and will benefit urologists, radiation oncologists, medical oncologists, physicists, and other health care professionals. It will educate the attendees about advances in management of localized and advanced prostate cancer.
• Determine which prostate cancer patients might benefit from active surveillance rather than definitive treatment
• Discuss the role of hormone therapy combined with chemotherapy in metastatic disease
• Describe technical advances, including robotic radical prostatectomy, image-guided external beam radiotherapy, proton beam therapy, hypofractionated radiotherapy, computer-guided brachytherapy, mpMRI, and demonstrate their roles in prostate cancer treatment and detection
• Identify appropriate patients for radiation-based treatments such as, brachytherapy IMRT/IGRT, proton therapy, robotic and open prostatectomy, and focal therapy taking serum and genetic influences into account
• Describe the role of therapeutic layering in advanced or castration-resistant prostate cancer and discuss treatment side effects
• Identify patients with low testosterone, testosterone replacement in prostate cancer patients, and describe benefits of penile rehabilitation in patients treated by radiotherapy and prostatectomy
Thursday, April 12, 2018
11:00am – 1:00pm Registration
1:00pm – 1:10pm Welcome and Introduction, Program Co-Chair: Nelson N. Stone, MD
1:10pm – 7:00pm SESSION I: Video Demonstrations/Biopsy Techniques, Moderator E. David Crawford, MD
1:10pm – 1:40pm Transrectal Fusion Biopsy Eigen/Artemis Technique, David M. Albala, MD
1:40pm – 2:10pm Transrectal Fusion Biopsy UroNav Technique, Peter A. Pinto, MD
2:10pm – 2:40pm 3D Biopsy Transperineal Mapping, E. David Crawford, MD
2:40pm – 3:10pm Permanent Prostate Brachytherapy, Richard G. Stock, MD
3:10pm-3:40pm Cryotherapy, John F. Ward, MD, FACS
3:40pm-4:00pm Break and Visit Exhibits
4:00pm-4:30pm MRI and Focal Therapy, John F. Ward, MD, FACS
4:30pm-5:00pm Mapping Biopsy and Focal Cryotherapy, E. David Crawford, MD
5:00pm - 5:30pm HIFU, John F. Ward, MD, FACS
5:30pm - 6:30pm Panel Discussion
7:00pm-9:00pm Welcome Reception and Exhibits
Friday, April 13, 2018
7:00am– 1:30pm Exhibits Open
7:00am - 8:00am Industry Breakfast Symposium
8:00am – 10:50am SESSION II: Initial Diagnosis and Active Surveillance, Moderator: Laurence Klotz, MD
8:00am – 8:25am Changing Distribution, Size and Grade of Prostate Cancer: Whole Mount Prostatectomy Analysis, M. Scott Lucia, MD
8:25am – 8:50am Can New Serum Markers Improve Biopsy Selection?, Gerald L. Andriole, Jr., MD
8:50am – 9:15am Toronto Experience of AS, Laurence Klotz, MD
9:15am – 10:00am Should MRI be Used to Monitor for AS? Pro: Peter A. Pinto, MD Con: Nelson N. Stone, MD
10:00am – 10:20am Prostate Biopsy: Techniques, Concerns and Precautions, Gerald L. Andriole, Jr., MD
10:20am – 10:40am Break and Visit Exhibits
10:40am – 11:00am Should Testosterone Levels Influence Decision to Biopsy?, Mohit Khera, MD, MBA, MPH
11:00am – 11:20am Update on Prostatectomy versus Observation Trials, Gerald L. Andriole, Jr., MD
11:20am – 12:20pm Panel Discussion
12:20pm – 12:30pm Break and Visit Exhibits
12:30pm – 1:30pm Industry Lunch Symposium
Saturday, April 14, 2018
8:00am – 3:00pm Exhibits Open
7:00am – 8:00am Industry Breakfast Symposium
8:00am – 2:00pm SESSION III: Focal Therapy, Moderator: John F. Ward, MD, FACS
8:00am – 8:20am Community Urologist Approach to Focal Therapy, David M. Albala, MD
8:20am – 8:40am Mapping Pathology as a Guide to Focal Therapy, M. Scott Lucia, MD
8:40am – 9:10am Focal Cryotherapy and HIFU, John F. Ward, MD, FACS
9:10am – 9:30am Focal Brachytherapy, Juanita M. Crook, MD, FRCPC
9:30am – 9:50am Intermittent or Continuous Hormone Therapy, Laurence I. Klotz, MD
9:50am – 10:10am Testosterone Replacement and Focal Therapy, Mohit Khera, MD, MBA, MPH
10:10am - 10:40am: Panel Discussion
10:40am – 11:00am Break and Visit Exhibits
11:00am – 2:00pm SESSION IV: Definitive Therapy, Moderator: Seth R. Blacksburg, MD
11:00am – 11:20am Genomic Markers: Can They Influence Type of Treatment, David M. Albala, MD
11:20am – 11:40am Hypofractionation, Seth R. Blacksburg, MD
11:40am – 12:00pm Prostatectomy: AS, USPST - What is the Future?, John F. Ward, MD, FACS
12:00pm – 12:20pm Long Term Outcomes of Permanent Brachytherapy, Nelson N. Stone, MD
12:20pm – 12:40pm Long-term Outcomes of HDR, Juanita M. Crook, MD, FRCPC
12:40pm – 1:00pm How Does Radiobiology Guide Dose, Fraction and Source Selection, Seth R. Blacksburg, MD
1:00pm - 1:20pm Preserving Erectile Function After Radiation and Surgery, Mohit Khera, MD, MBA, MPH
1:20pm – 2:00pm Panel Discussion
2:00pm – 3:00pm Industry Lunch Symposium or Ad Board
Evening on Own (Faculty Dinner)
Sunday, April 15, 2018
7:00am - 8:00am Industry Breakfast Symposium
8:00am – 10:00am SESSION V: Advanced Disease, Moderator: Daniel P. Petrylak, MD
8:00am – 8:30am Determining Patterns of Failure: Advanced Imaging, Richard G. Stock, MD
8:30am – 9:00am Early Chemotherapy with Advanced Disease, Daniel P. Petrylak, MD
9:00am – 9:30am Adjuvant or Salvage RT post Radical Prostatectomy, Seth R. Blacksburg, MD
9:30am – 10:00am Sequencing of Adjuvant Therapies, Daniel P. Petrylak, MD
10:00am – 12:45pm SESSION VI: Quality of Life and Men’s Health, Moderator: Nelson N. Stone, MD
10:00am – 10:20am Does RT Favor RP in Long-Term QOL?, Juanita M. Crook, MD, FRCPC
10:20am – 10:50am Long-Term Erectile Dysfunction and Urinary Morbidity Following Brachytherapy, Nelson N. Stone, MD
10:50am – 11:20am Prevention and Management of Rectal Toxicity, Richard G. Stock, MD
11:20am – 1:00pm Panel and Case Management
To make your hotel reservation, please contact the Scottsdale Plaza at 800-832-2025 and request the Reservations Department. Mention that you are attending the Carden Jennings Publishing “Scottsdale Prostate Cancer Symposium 2018.”
A block of rooms has been reserved at the Scottsdale Plaza for the nights of Wednesday, Thursday, Friday, and Saturday, April 12-15, 2018, at a discounted rate, single or double occupancy. A limited number of rooms are available for this group, so reservations will be accepted on a first-come, first-served basis.
To receive your discounted rate, please reference the group code “Scottsdale Prostate Cancer Symposium 2017.” Full payment is required on the date the reservation is made. Full payment for room and tax is refunded if notice is received no later than 30 days in advance of the confirmed arrival date. No-shows and early departure/late arrivals will be charged for their full reservation.
Nelson N. Stone, MD, Professor of Urology and Radiation Oncology, Icahn School of Medicine at Mount Sinai, CEO and President of 3D Biopsy, Inc., New York, New York
Richard G. Stock, MD, Professor of Radiation Oncology, Director of Genito-Urinary Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
David M. Albala, MD, Crouse Hospital, Associated Medical Professionals, Syracuse, NY
Gerald L. Andriole, Jr., MD, Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO
Seth R. Blacksburg, MD, NYU Winthrop Hospital, New York, NY
E. David Crawford, MD, University of Colorado, Denver, Aurora, CO
Juanita M. Crook, MD, FRCPC, University of British Columbia, Kelowna, BC, Canada
Mohit Khera, MD, MBA, MPH, Baylor College of Medicine, Houston, TX
Laurence Klotz, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
M. Scott Lucia, MD, University of Colorado, Denver
Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT
Peter A. Pinto, MD, National Institutes of Health, Bethesda, MD
John F. Ward, MD, FACS, University of Texas MD Anderson Cancer Center, Houston, TX
Disclosure of Conflicts of Interest
It is the policy of Medical College of Wisconsin to insure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MCW identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MCW to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
CJP Medical Communications Disclosure
The employees of CJP Medical Communications have no financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, Carden Jennings Publishing, or the program supporters.
Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically, and are encouraged to consult appropriate resources for any product or device mentioned in this program.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and CJP Medical Communications. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 21.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 21.25 Hours of ParticipationHours of Participation credit.